(Total Views: 370)
Posted On: 11/04/2024 11:02:28 PM
Post# of 147996
Quote:
A surrogate endpoint....
The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint.
In the case of mssCRC and Alzheimer's it would be proof in clinical endpoints backed up by surrogate endpoints. What would hinder mssCRC is unmet need.
(3)
(0)Scroll down for more posts ▼
